Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cyano-Pyrrolidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyano-Pyrrolidine SCHEMBL5076708 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL8584979 | 0.97 | CTSL (0.87) | — | |
| Hydrochloric Acid SCHEMBL28173618 | 0.97 | — | — | |
| Cyano-Pyrrolidine SCHEMBL297005 | 0.96 | — | — | |
| SCHEMBL311224 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL2579725 | 0.93 | — | — | |
| SCHEMBL10274655 | 0.93 | — | — | |
| SCHEMBL3428433 | 0.89 | — | — | |
| Ethane SCHEMBL28010291 | 0.83 | CTSK (0.87) | — | |
| Cyano-Pyrrolidine SCHEMBL17686049 | 0.82 | CTSL (0.72) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3023095-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis AG (CH) | 2016-05-25 | — | — | EP | claimed |
| EP-2839832-A2 | Use of dipeptidyl peptidase IV inhibitors | Novartis AG (CH) | 2015-02-25 | — | — | EP | claimed |
| US-20130052239-A1 | Formulation | JOSHI YATINDRA (US) | 2013-02-28 | — | — | US | claimed |
| US-20110301172-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFORMIN | BURKEY BRYAN (US) | 2011-12-08 | — | — | US | claimed |
| EP-2165703-A2 | Direct compression formulation and process | Novartis Pharma AG. (CH) | 2010-03-24 | — | — | EP | claimed |
| US-20090253752-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN | BURKEY BRYAN | 2009-10-08 | — | — | US | claimed |
| US-20080299190-A1 | Direct Compression Formulation and Process | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | claimed |
| US-20080193529-A1 | Direct Compression Formulation and Process | KOWALSKI JAMES | 2008-08-14 | — | — | US | claimed |
| EP-1893236-A2 | DIRECT COMPRESSION FORMULATION OF DPP-IV INHIBITORS AND GLITAZONES, AND PROCESS | Novartis AG (CH) | 2008-03-05 | — | — | EP | claimed |
| EP-1841413-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis AG (CH) | 2007-10-10 | — | — | EP | claimed |
| WO-2006135693-A2 | DIRECT COMPRESSION FORMULATION OF DPP-IV INHIBITORS AND GLITAZONES, AND PROCESS | NOVARTIS AG (CH) | 2006-12-21 | — | — | WO | claimed |
| EP-1715893-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis Pharma AG. (CH) | 2006-11-02 | — | — | EP | claimed |
| US-20060210627-A1 | Direct compression formulation and process | PFEFFER SABINE | 2006-09-21 | — | — | US | claimed |
| EP-1686994-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| EP-1687030-A2 | COMBINATION OF A DPP IV INHIBITOR AND AN ANTI-OBESITY OR APPETITE REGULATING AGENT | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2006078593-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2006-07-27 | — | — | WO | claimed |
| WO-2006047248-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METFORMIN | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | claimed |
| WO-2005067976-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | claimed |
| WO-2005049022-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |
| WO-2005049088-A2 | COMBINATION OF A DPP IV INHIBITOR AND AN ANTIOBESITY OR APPETITE REGULATING AGENT | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |